BET bromodomain inhibitors synergize with ATR inhibitors to induce DNA damage, apoptosis, senescence-associated secretory pathway and ER stress in Myc-induced lymphoma cells

Oncogene
Somsundar Veppil MuralidharanJonas A Nilsson

Abstract

Inhibiting the bromodomain and extra-terminal (BET) domain family of epigenetic reader proteins has been shown to have potent anti-tumoral activity, which is commonly attributed to suppression of transcription. In this study, we show that two structurally distinct BET inhibitors (BETi) interfere with replication and cell cycle progression of murine Myc-induced lymphoma cells at sub-lethal concentrations when the transcriptome remains largely unaltered. This inhibition of replication coincides with a DNA-damage response and enhanced sensitivity to inhibitors of the upstream replication stress sensor ATR in vitro and in mouse models of B-cell lymphoma. Mechanistically, ATR and BETi combination therapy cause robust transcriptional changes of genes involved in cell death, senescence-associated secretory pathway, NFkB signaling and ER stress. Our data reveal that BETi can potentiate the cell stress and death caused by ATR inhibitors. This suggests that ATRi can be used in combination therapies of lymphomas without the use of genotoxic drugs.

References

Oct 1, 1988·Molecular and Cellular Biology·T K Kerppola, C M Kane
Oct 25, 1996·The Journal of Biological Chemistry·N F MarshallD H Price
Aug 24, 2000·International Journal of Cancer. Journal International Du Cancer·A PajicD Eick
Jul 4, 2003·Proceedings of the National Academy of Sciences of the United States of America·Anup DeyKeiko Ozato
Nov 19, 2004·The Biochemical Journal·Anupama SinhaGerald V Denis
Jun 9, 2005·Oncogene·Ulrich KellerJohn L Cleveland
Dec 24, 2008·Molecular and Cellular Biology·Bo HuangLin-Feng Chen
Jun 16, 2009·Cell·Jorge Moscat, Maria T Diaz-Meco
Jul 25, 2009·Blood·Kay KlapprothThomas Wirth
Jul 6, 2010·BMC Cancer·Ulrich KellerJohn L Cleveland
Apr 15, 2011·Nature Chemical Biology·Philip M ReaperJohn R Pollard
May 10, 2011·Nature Structural & Molecular Biology·Luis I ToledoOscar Fernandez-Capetillo
Sep 6, 2011·Cell·Jake E DelmoreConstantine S Mitsiades
Sep 22, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Andreas HöglundJonas A Nilsson
Sep 29, 2011·Proceedings of the National Academy of Sciences of the United States of America·Jennifer A MertzRobert J Sims
Nov 29, 2011·Nature Structural & Molecular Biology·Matilde MurgaOscar Fernandez-Capetillo
Jun 23, 2012·Nature Reviews. Cancer·Anna C Belkina, Gerald V Denis
Feb 14, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Zhixiang ChengJialiang Wang
Feb 23, 2013·Cancer Discovery·Alexandre PuissantKimberly Stegmaier
Dec 4, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Pratiti BandopadhayayYoon-Jae Cho
Feb 6, 2014·Epigenetics : Official Journal of the DNA Methylation Society·Chiara PastoriNagi G Ayad
Mar 4, 2014·Nature Chemical Biology·Pietro CiceriStefan Knapp
Jun 17, 2014·Oncotarget·Marie LoosveldDominique Payet-Bornet
Jul 1, 2014·Proceedings of the National Academy of Sciences of the United States of America·Joydeep BhaduryJonas A Nilsson
Sep 5, 2014·Cancer Immunology Research·Chad TangJames W Welsh

❮ Previous
Next ❯

Citations

Aug 24, 2016·The Prostate·Balabhadrapatruni V S K ChakravarthiSooryanarayana Varambally
Feb 15, 2017·Journal of Medicinal Chemistry·Zhiqing LiuJia Zhou
Apr 11, 2017·Oncogene·G RaschellàM Malewicz
Mar 16, 2019·Immunological Reviews·Andrea BissoBruno Amati
Oct 11, 2016·Oncogene·T TsuruyamaN Yamada
Aug 26, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D B DoroshowP M LoRusso
Aug 11, 2017·Cell Death & Disease·Somsundar Veppil MuralidharanJonas A Nilsson
May 8, 2020·Journal of Experimental & Clinical Cancer Research : CR·S L GeorgeL Chesler
Jun 15, 2018·Nature Reviews. Cancer·Emilio Lecona, Oscar Fernandez-Capetillo
Feb 15, 2019·Frontiers in Oncology·Fernando Vieira PericoleSara Teresinha Olalla Saad
Jul 18, 2019·Journal of Hematology & Oncology·Yunlu JiaJianbiao Zhou
May 18, 2016·Journal of Cellular Physiology·Samantha M MillerGary L Johnson
Mar 7, 2019·Nature Reviews. Clinical Oncology·David SermerAnas Younes
Aug 29, 2020·Genes·Huanbo ZhuJun Zhang
Mar 29, 2020·Cancers·Durga Khandekar, Venkataswarup Tiriveedhi
Sep 7, 2020·Cancer Treatment Reviews·Laura CarrassaFrancesco Bertoni
Jan 14, 2020·Pharmacology & Therapeutics·Oliver Bechter, Patrick Schöffski
Feb 26, 2021·Frontiers in Pharmacology·Lan-Ya LiYan Cheng
Jul 22, 2021·Communications Biology·Carol Lai-Hung ChengChun-Ming Wong

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Ataxia telangiectasia

Ataxia telangiectasia is a rare neurodegenerative diseases caused by defects in the ATM gene, which is involved in DNA damage recognition and repair pathways. Here is the latest research on this autosomal recessive disease.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Cancer -Omics

A variety of different high-throughput technologies can be used to identify the complete catalog of changes that characterize the molecular profile of cohorts of tumor samples. Discover the latest insights gained from cancer 'omics' in this feed.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Ataxia telangiectasia (MDS)

Ataxia telangiectasia is a rare neurodegenerative diseases caused by defects in the ATM gene, which is involved in DNA damage recognition and repair pathways. Here is the latest research on this autosomal recessive disease.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.